.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has actually decided on Eli Lilly (NYSE: LLY) as its best biopharma selection for 2025 as well as measured yet another nine titles in the space as over weight. The investment bank mentioned in a note that it remains to feel “diabesity is actually readied to become.